Stockreport

TScan Therapeutics Inc (TCRX) Reports Increased Revenue and Expands Clinical Pipeline [Yahoo! Finance]

TScan Therapeutics, Inc.  (TCRX) 
PDF R&D Investments : R&D expenses increased to $22.4 million in Q4 and $88.2 million for the full year, reflecting clinical trial and personnel costs. G&A Expenses : Gen [Read more]